Cargando…

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery

Background: Weight loss before undergoing metabolic and bariatric surgery (MBS) has been suggested to reduce perioperative complications, although with controversial results. The objective of this study is to evaluate the impact of treatment with GLP1-R agonists (liraglutide 3.0 mg and semaglutide 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubio-Herrera, Miguel A., Mera-Carreiro, Sara, Sánchez-Pernaute, Andrés, Ramos-Levi, Ana M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604375/ https://www.ncbi.nlm.nih.gov/pubmed/37893158 http://dx.doi.org/10.3390/biomedicines11102785

Ejemplares similares

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
por: Wharton, Sean, et al.
Publicado: (2019)

Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
por: Muratori, Fabrizio, et al.
Publicado: (2022)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
por: Evans, Marc, et al.
Publicado: (2023)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
por: Overgaard, Rune V., et al.
Publicado: (2016)

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
por: Wharton, Sean, et al.
Publicado: (2019)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
por: Allison, Kelly C., et al.
Publicado: (2022)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker, Waleed, et al.
Publicado: (2021)

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
por: Ko, Hae-Jin, et al.
Publicado: (2022)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers
por: Fujioka, Ken, et al.
Publicado: (2016)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
por: Wharton, Sean, et al.
Publicado: (2020)

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
por: Wharton, Sean, et al.
Publicado: (2020)

Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
por: Santini, Sara, et al.
Publicado: (2022)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways
por: Rakipovski, Günaj, et al.
Publicado: (2018)

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
por: Wadden, Thomas A., et al.
Publicado: (2020)

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis
por: Konwar, Mahanjit, et al.
Publicado: (2022)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

Effect of Microstructure Refinement on the Corrosion Behavior of the Bioresorbable Mg-1Zn-0.2Ca and Mg-1Ca Alloys
por: Kulyasova, Olga B., et al.
Publicado: (2022)

Investigation of the Hemostatic Effect of a Transdermal Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene Compared with a Monophasic Oral Contraceptive Containing 0.03 mg Ethinyl Estradiol and 0.15 mg Levonorgestrel: An Open-Label, Randomized, Crossover Study
por: Junge, Wolfgang, et al.
Publicado: (2013)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Cardiovascular effect of dental anesthesia with articaine (40 mg with epinefrine 0,5 mg % and 40 mg with epinefrine 1 mg%) versus mepivacaine (30mg and 20 mg with epinefrine 1 mg%) in medically compromised cardiac patients: A cross-over, randomized, single blinded study
por: Torres-Lagares, Daniel, et al.
Publicado: (2012)

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
por: O'Neil, Patrick M., et al.
Publicado: (2017)

Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity
por: Kolotkin, R. L., et al.
Publicado: (2017)

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
por: Papathanasiou, Theodoros, et al.
Publicado: (2020)

Improving Adherence to Weight‐Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support
por: Li, Ang, et al.
Publicado: (2020)

Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
por: Tempia Valenta, Silvia, et al.
Publicado: (2023)

Efficacy of 4.0 mg versus 0.4 mg Folic Acid Supplementation on the Reproductive Outcomes: A Randomized Controlled Trial
por: Bortolus, Renata, et al.
Publicado: (2021)

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
por: Capehorn, Matthew, et al.
Publicado: (2021)

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nie2c8vqg3c27afp21b5clvn8u